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Abstract
Different forms of regulated cell death-like apoptosis and necroptosis contribute to the pathophysiology of clinical
conditions including ischemia-reperfusion injury, myocardial infarction, sepsis, and multiple sclerosis. In particular, the
kinase activity of the receptor-interacting serine/threonine protein kinase 1 (RIPK1) is crucial for cell fate in inﬂammation
and cell death. However, despite its involvement in pathological conditions, no pharmacologic inhibitor of RIPK1-mediated
cell death is currently in clinical use. Herein, we screened a collection of clinical compounds to assess their ability to
modulate RIPK1-mediated cell death. Our small-scale screen identiﬁed the anti-epilepsy drug Phenhydan® as a potent
inhibitor of death receptor-induced necroptosis and apoptosis. Accordingly, Phenhydan® blocked activation of necrosome
formation/activation as well as death receptor-induced NF-κB signaling by inﬂuencing the membrane function of cells, such
as lipid raft formation, thus exerting an inhibitory effect on pathophysiologic cell death processes. By targeting death
receptor signaling, the already FDA-approved Phenhydan® may provide new therapeutic strategies for inﬂammation-driven
diseases caused by aberrant cell death.
Introduction
Cell death plays a signiﬁcant role in a variety of human dis-
eases, determining the extent of tissue destruction and, in turn,
organ function [1]. The past decade has witnessed signiﬁcant
expansion of our understanding of regulated cell death beyond
apoptosis. Programmed necrosis such as necroptosis, which is
characterized by plasma membrane rupture and the release of
intracellular contents, is an alternate cell death pathway that
has been demonstrated to eliminate cells when caspase activity
is limited [2]. Furthermore, it has been established that
receptor-interacting serine/threonine protein kinase (RIPK) 1,
its related kinase RIPK3, and its substrate Mixed lineage
kinase domain-like protein (MLKL) constitute the core of the
necroptosis machinery, termed the necrosome [3–6]. RIPK1
can be activated by multiple triggers, including signaling by
members of the TNF family of cytokines such as TNFα,
TLR3 and 4, Interferon receptors, and certain pathogens [7–9].
RIPK1-mediated cell death is best characterized for TNF
receptor 1 (TNFR1), and phosphorylation of the necrosome
components RIPK1, RIPK3, and MLKL at different sites is a
hallmark of the induction of necroptosis [10]. However, cell
death is not the only signaling outcome for this receptor; in
fact, NF-κB activation is often the dominant response of death
receptors.
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Increasing evidence from genetic and pharmacologic
analyses has shown that RIPK1-induced cell death is a
driver of inﬂammation and contributes to the progression of
many cell death-associated conditions, such as myocardial
infarction, stroke, sepsis, viral infections, hepatitis, and
ischemia-reperfusion injury (IRI), which is an unavoidable
consequence after kidney transplantation. Of course, the
development of selective therapeutics for all these disorders
would be of overriding relevance. However, no pharmaco-
logic inhibitor of RIPK1-mediated cell death is currently in
clinical use.
The highly efﬁcient RIPK1 inhibitor 5-(indol-3-ylme-
thyl)-3-methyl-2-thio-hydantoin, herein termed necrostatin-
1 (Nec-1), was identiﬁed in 2005 as the ﬁrst compound to
block necroptotic cell death in human and murine cells [11].
It inhibits the kinase activity of RIPK1, and its protective
effect against different cell death scenarios was widely
interpreted as conﬁrmation of the occurrence of necroptosis.
However, because of its short plasma half-life, in vivo
studies examining the therapeutic effects of Nec-1 are
extremely scarce. Nec-1 was later discovered to be chemi-
cally identical to methyl-thiohydantoin-tryptophan, an
inhibitor of the potent immunomodulatory enzyme indo-
leamine 2,3-dioxygenase (IDO) [12], which means that
Nec-1 can exert effects on the immune system that are
independent of the inhibition of the kinase activity of
RIPK1. Nec-1s, an enhanced stable analogue of Nec-1 that
does not target IDO, has a much longer half-life in vivo, and
is able to interfere with RIPK1-dependent processes, was
developed [12]. Necrostatins fail to block necroptosis in the
absence of RIPK1 [13], eliminating the therapeutic appli-
cation of Nec-1s for RIPK1-independent necroptosis.
However, a further RIPK1 inhibitor, GSK2982772, has
been developed and is currently undergoing Phase-IIa
clinical trials for the treatment of inﬂammatory diseases
such as psoriasis and inﬂammatory bowel disease [14].
Investigators have proposed that RIPK3 represents a
more promising target in this scenario of regulated cell
death: it is assumed that suppression of the necroptotic
pathway at the level of RIPK3 rather than RIPK1 will be
more speciﬁc and offer greater therapeutic beneﬁts. Indeed,
pharmacologic inhibitors that target the kinase function of
RIPK3, such as the small-molecule inhibitors GSK’843,
GSK’872, GSK’840, dabrafenib, and ponatinib, have been
crucial in demonstrating the importance of RIPK3 kinase
activity for necroptosis [7, 15, 16]. Nevertheless, high doses
of some of these drugs can induce RIPK3-dependent
apoptosis, which is consistent with the observation that
mice that express D161N RIPK3, a catalytically inactive
form of RIPK3, die during embryogenesis [17], likely
owing to an inability to suppress RIPK1-directed cell death
allosterically [18]. These characteristics limit the potential
of these inhibitors as therapeutic drugs for the suppression
of regulated cell death. However, mice that express an
alternate kinase-dead RIPK3 protein harboring a different
point mutation, K51A, develop normally and survive to
adulthood [19], which suggests that pharmacologic sup-
pression of RIPK3 kinase activity without inducing apop-
tosis is feasible.
Necrosulfonamide (NSA), a cell-permeable acrylamide
compound that inhibits human, but not murine, MLKL
adaptor function via covalent modiﬁcation of C86, has been
successfully used to block necroptosis in vitro [6]. How-
ever, NSA contains a reactive moiety and is therefore highly
promiscuous. For this reason, no clinical trials have been
registered to evaluate its efﬁcacy in an in vivo setting to
date.
All of these promising inhibitors of the necrosome
components RIPK1, RIPK3, and MLKL lack legal
approval, which precludes their application for preclinical
RIPK1-mediated diseases and reduces their therapeutic
value in patients. Thus, we investigated whether drugs
already approved and in clinical use were suited to the
inhibition of regulated cell death processes. The underlying
rationale is that the pharmacokinetics, side effects and
safety proﬁles of such FDA-approved drugs are already well
documented for therapeutic applications. The drugs exam-
ined in this study were considered independently of their
current clinical applications, and their effects were com-
pared with those of the potent RIPK1 kinase inhibitor Nec-
1s. Our data identify the mechanisms of Phenhydan®-
mediated prevention of death receptor-induced regulated
cell death and indicate that an inhibitor of cell death-
associated diseases is readily available for clinical
application.
Results
To identify an FDA-approved drug that could be used for
the treatment of pathophysiologic cell death processes, we
selectively screened a small set of clinically approved
compounds. In particular, we focused on drugs that are
structurally related to Nec-1. To this end, we ﬁrst tested the
unsubstituted heterocyclic aromatic compound imidazole
and its derivative hydantoin. We found that these exhibited
no inhibitory effect on necroptosis in a range of necroptosis-
sensitive cell lines (Fig. 1a–d). Next, we focussed on het-
erocyclic compounds, which constitute nearly 70% of active
pharmaceuticals [20]. Particularly, we tested the effect of
barbiturates, which are a class of drugs that produce effects
ranging from mild sedation to anesthesia and are used to
treat acute convulsive episodes requiring emergency inter-
vention. Intriguingly, barbiturates such as Brevimytal® and
Luminal® delayed but did not inhibit TNF-induced and
RIPK1-mediated cell death in murine L929 cells (Fig. 1e, f).
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While Luminal® delayed necroptosis, the more potent
structural analogue phenytoin (Phenhydan®), which is
widely used as antiepileptic, as well as in a broad spectrum
of neurologic disorders [21], protected murine L929 cells
from TNF-induced cell death in a dose-dependent manner,
and for longer time points (Fig. 1g). Phenhydan® not only
inhibited RIPK1-mediated cell death in L929 cells but also
in murine NIH3T3 as well as human HT-29, and U937
cells, expanding this observation to multiple cell types and
species (Fig. 2a–d). In contrast to Phenhydan®, a class of
related benzodiazepines and benzodiazepine derivatives
with an imidazole structure, such as Tavor® and Dormicum®,
did not exhibit any detectable effect on TNF-mediated cell
death (data not shown), suggesting that the observed cell
death suppression is speciﬁc to Phenhydan® (all substances
described and tested in this work, including their structural
formulae, are listed in Supplementary Table 1).
Consistent with the notion that Phenhydan® provides
protection from RIPK1-mediated cell death, we found that
Phenhydan® treatment suppressed phosphorylation and
activation of RIPK1 (p-S166), RIPK3 (p-S227 in human
and p-T231/S232 in murine cells) and MLKL (p-S358 in
human and p-S345 in murine cells) in these cells (Fig. 2a–
d). The inhibitory properties of Phenhydan® on TNF-
induced cell death were also evident in primary cells such as
bone marrow-derived macrophages (BMDCs) and mouse
embryonic ﬁbroblasts (MEFs) (Supplementary Fig. 1). The
protective effect of Phenhydan® in TNF-induced cell death
was found to be as potent as that of the laboratory estab-
lished but not FDA-approved inhibitors Nec-1s (RIPK1),
GSK’872 (RIPK3) and GW806742X (murine MLKL) [22].
Accordingly, we evaluated and illustrated the potent effect
of Phenhydan® in TZ-induced cell death and directly com-
pared its effects with the aforementioned commercially
available inhibitors (Supplementary Fig. 2).
Since Phenhydan® suppressed auto-phosphorylation of
S166 in RIPK1 following TNF treatment, our data suggest
that Phenhydan® suppresses early activation of RIPK1 in the
TNF receptor signaling complex-I, and that Phenhydan®
might suppress TNFR1-signaling in general. Therefore, we
evaluated whether Phenhydan® affects TNF-induced NF-κB
signaling. Treatment of primary MEFs with TNF in the pre-
sence and absence of Phenhydan® demonstrated that sequen-
tial phosphorylation of IκBα, p65/RelA, p38 MAPK, MAPK-
activated protein kinase-2 (MK2), and JNK after TNF sti-
mulation was largely suppressed by Phenhydan® (Fig. 3a).
This strongly suggests that Phenhydan® interferes with
TNFR1 signaling. To test whether Phenhydan® affects the
recruitment of RIPK1 into TNF receptor signaling complex-I,
we stimulated cells with TNF and isolated complex-I. As
shown in Fig. 3b, Phenhydan® decisively reduced the
recruitment and ubiquitylation of RIPK1 in complex-I.
Fig. 1 Representative selection of imidazole and hydantoin derivatives
based on their inhibitory effect in the course of RIPK1-dependent cell
death. a, c Murine L929 and NIH3T3 cells were stimulated at 37 °C
for 16 h with 100 ng/ml TNFα+ 25 µM zVAD (TZ) in the absence or
presence of different concentrations (as indicated) of unsubstituted
imidazole and its derivative hydantoin, respectively. b, d For the
induction of RIPK1-dependent necroptosis, human HT-29 and U937
cells were stimulated at 37 °C for 16 h with 100 ng/ml TNFα+ 1 µM
SMAC mimetic SM164+ 25 µM zVAD (TSZ) in the absence or
presence of the indicated amounts of imidazole and hydantoin. In each
case, aromatic compounds were added 30 min before the induction of
necroptosis. (E-G) L929 ﬁbroblasts were stimulated at 37 °C for 4, 8,
and 16 h with 100 ng/ml TNFα+ 25 µM zVAD (TZ) in the absence or
presence of Brevimytal® (e), Luminal® (f), or Phenhydan® (g). Each
drug was added 30 min before TZ stimulation. Necroptotic cell death
was quantiﬁed by FACS analysis using 7-amino-actinomycin D and
phosphatidylserine accessibility (Annexin V staining) as markers.
Graphs show the mean ± SEM; n= 4 independent experiments
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Furthermore, subsequent, time-dependent recruitment of
cIAP1 and SHARPIN to the TNFR1 complex upon the
addition of TNF was markedly diminished in the presence of
Phenhydan® (Fig. 3b). The formation of an abnormal
TNFR1 signaling complex in the presence of Phenhydan®
may help to explain the inhibitory effect of the drug on
RIPK1-mediated cell death. With regard to the mechanism, it
is possible that Phenhydan® treatment prevents the autopho-
sphorylation of RIPK1 (a major function of RIP1 kinase in
TNF-induced cell death), which enables RIPK1 to recruit
RIPK3 and form a functional necrosome [23].
Next, we tested whether Phenhydan® interfered like eta-
nercept (Enbrel®) and inﬂiximab (Remicade®) with the
binding of TNF to TNFR1. Nonetheless, an examination of
the internalization kinetics of TNFR1 using labeled TNFα
(Fig. 3c) and quantiﬁcation of this internalization 30 min
after ligand binding (Fig. 3d) excluded this possibility. Flow
cytometry analysis of TNFR1 on the plasma membrane
surface after labelling it with biotinylated TNFα/Alexa
Fluor™ 488-conjugated Streptavidin revealed only a
slightly lower ﬂuorescence intensity in cells pretreated with
Phenhydan® than in vehicle-treated cells (Fig. 3e, upper
left). This outcome was in accordance with earlier data on
TNF binding and internalization of the ligand/receptor
complex, which were not markedly affected by Phenhydan®.
To explain how Phenhydan® exerts its pharmacologic
effects, at least in the context of TNF-mediated signaling,
we explored whether this drug induces reorganization of the
signaling machinery on the cell surface. The dynamic
changes in plasma membranes can be resolved in real time
by using lipophilic dyes that are readily incorporated into
lipid structures. For our experiments, we used CellMask™
plasma membrane stains, which provide excellent and rapid
plasma membrane staining in live cells without any cell-
type differences exhibited by Lectins. The dye does not
have any biological function but shows strong ﬂuorescence
only when intercalated into the hydrophobic core of a bio-
logical membrane. The ﬂuorescence spectrum presented in
Fig. 3e (upper right) clearly indicates that the membrane
structure of the cells, deﬁned as changes in lipid order, is
signiﬁcantly affected in the presence of Phenhydan®. To
eliminate concerns that Phenhydan® does not mediate a
protective effect at the cellular level but only prevents
interaction of CellMask™ with the cell surface, we mon-
itored the ﬂuorescence spectrum of CellMask™ before and
after the addition of 1 mM Phenhydan® to U937 cells for up
to 1 h. Methyl-β-cyclodextrin (MβCD), which is a standard-
approved cholesterol-depleting agent, served as an internal
control. The data in Supplementary Fig. 3a clearly
demonstrate that Phenhydan® does not exert its effect
Fig. 2 Species-independent conﬁrmation of the inhibitory properties of
Phenhydan® in the course of necroptosis. Each probe was split for
FACS analysis (left) and corresponding western blotting (right). a
Murine L929 and murine NIH3T3 cells were stimulated at 37 °C for
up to 8 h with 100 ng/ml TNFα+ 25 µM zVAD (TZ) in the absence or
presence of 1 mM Phenhydan®. For the induction of necroptosis,
human HT-29 and human U937 cells were stimulated at 37 °C for up
to 8 h with 100 ng/ml TNFα+ 1 µM SMAC mimetic SM164+ 25 µM
zVAD (TSZ) in the absence or presence of 1 mM Phenhydan®,
wherein the drug Phenhydan® was added 30 min before the induction
of necroptosis. Necroptotic cell death was quantiﬁed by FACS analysis
using 7-amino-actinomycin D and phosphatidylserine accessibility
(Annexin V staining) as markers. Graphs show the mean ± SEM; n= 4
independent repeats. The whole expression level and activation status
(phosphorylation) of the indicated necrosome member receptor-
interacting serine/threonine protein kinase 1, receptor-interacting ser-
ine/threonine protein kinase 3, and Mixed lineage kinase domain-like
protein after necroptosis in the absence or presence of Phenhydan®
were analyzed by western blotting, using the indicated speciﬁc anti-
bodies. Notably, identical samples (time courses of different cell lines)
to those analyzed by FACS were used in this approach. All blots were
each re-developed with an antibody against β-actin as a loading con-
trol. One representative blot of four independent experiments is shown
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merely by preventing the binding of the plasma membrane
dye CellMask™ to the cell surface.
Our results so far are consistent with the notion that lipid
rafts are essential for TNFα-mediated activation of TNFR1
but dispensable for the activation of the NF-κB and MAPK
pathways [24]. The plasma membrane is composed of dis-
crete lipid microdomains in which membrane molecules are
differentially partitioned [25]. Therefore, we used the
ﬂuorescein-labeled cholera toxin B subunit (CTxB) to
determine whether Phenhydan® engagement affects the
distribution of rafts, thereby leading to the alteration of cell
death receptor signaling. The binding of CTxB to
ganglioside GM1, which is enriched in lipid rafts, is con-
sidered as a marker of lipid rafts [26]. As shown in Fig. 3e,
the ﬂuorescence intensity of CTxB is markedly declined in
the presence of Phenhydan®; this supports our hypothesis
that the drug leads to increased disruption of lipid rafts.
Accordingly, we noticed a distinct decrease in the activity
of ASMase in the presence of Phenhydan®; this additionally
indicates disruption of TNF-signaling downstream of
TNFR1 (Fig. 3f).
It has been proposed that TNF receptor-mediated sig-
naling relies on lipid-raft integrity [27]. Upon TNF binding,
TNFR1 appears to translocate into these specialized
Fig. 3 Phenhydan® prohibits canonical NF-κB signaling by inﬂuencing
the membrane function of cells. Primary MEFs were treated in the
absence or presence of 1 mM Phenhydan® with 10 ng/ml TNFα for the
indicated durations. Phenhydan® was added 30 min before the addition
of TNFα. a Western blotting analysis of the cell lysates using the
indicated antibodies. b TNFα-induced complex-I immunoprecipitation
(IP) of primary MEFs treated in the absence or presence of 1 mM
Phenhydan® with 1 µg/ml FLAG-tagged TNFα for the indicated
durations, followed by FLAG IP and western blotting analysis using
the indicated antibodies. c Deranged TNF receptor 1 (TNFR1) sig-
naling in the presence of Phenhydan® was ruled out by IP of TNFR1.
Cells were treated in the absence or presence of 1 mM Phenhydan®
with 100 ng/ml Fc-tagged TNFα for the indicated time points, fol-
lowed by IP and western blotting analysis using a speciﬁc anti-TNFR1
antibody. d Quantiﬁcation of TNFR1 internalization is described in the
Materials and Methods section. Labelling of TNFR1 with 100 ng/ml
biotinylated-TNFα and 5 µg/ml Alexa Fluor™ 488-conjugated Strep-
tavidin was analyzed over time. The 30 min value ± Phenhydan® is
shown representative for imaging ﬂow cytometry. e CellMask™ Deep
Red plasma membrane staining and subsequent cell analysis revealed
the Phenhydan®-mediated changes in the lipid bilayer properties,
whereas staining in the presence of cholera toxin subunit B (CTxB)
conﬁrms that Phenhydan® leads to the disruption of lipid rafts on the
cell surface. f Acid sphingomyelinase (ASMase) activity assay indi-
cates a distinct decreased activity of ASMase in the presence of
Phenhydan®. g U937 cells were incubated at 37 °C for 30 min with 1
mM Phenhydan® and 10 mM methyl-β-cyclodextrin (MβCD), whereas
control cells were vehicle-treated. Membrane lipid rafts and the
detergent-soluble fraction were isolated by sucrose gradient cen-
trifugation. From the top of the gradient, 1-ml sucrose gradient frac-
tions were obtained and analyzed by western blotting for the indicated
proteins
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membrane compartments, which are enriched in sphingoli-
pids and cholesterol and serve as sorting platforms for
signal transduction proteins. To substantiate our ﬁnding that
lipid rafts and membrane composition are affected by
Phenhydan®, we performed sucrose density gradient cen-
trifugation to distinguish between lipid raft and non-lipid
raft fractions. To this end, we isolated lipid rafts from whole
cells (pretreated ± Phenhydan®) and analyzed TNFR1 loca-
lization in the separate segregated fractions. Flotillin-2 was
used as a lipid raft-associated marker [28]. As shown in
Fig. 3g, in the absence of Phenhydan®, TNFR1 was abun-
dant in Fractions 3 and 4, representing the detergent-inso-
luble, glycolipid-enriched microdomains. This outcome is
consistent with previous reports that TNFR1 can be
recruited to lipid raft-containing fractions [29, 30]. How-
ever, in the presence of Phenhydan®, little if any TNFR1
was localized to the rafts (Fractions 3 and 4) and instead
accumulated in the soluble fraction (Fractions 6 and 7).
Treatment with methyl-β-cyclodextrin (MβCD), which is
often used to disrupt lipid rafts [31], led to acute depletion
of cholesterol from the plasma membrane; thus, the effect of
MβCD resembled that of Phenhydan®. However, when it
was used in an equimolar concentration to Phenhydan® (1
mM), it did not exhibit an inhibitory effect on TNF-
mediated cell death (Supplementary Fig. 3b). Nevertheless,
it should be mentioned that for effective disorganization of
the lipid rafts, as shown before in Fig. 3g, MβCD must be
used in a 10-fold higher concentration (10 mM). However,
at such a high concentration, it is known [32] that MβCD is
toxic to a wide variety of cells already even with a short
period of incubation (<1 h). This prevents a direct com-
parison of the mechanism of MβCD and Phenhydan®, with
regard to their inhibitory effects in the course of ongoing
(>5 h) necroptosis.
Of note, Phenhydan® had no effect on erastin- or RSL3-
induced ferroptosis [22], suggesting that the drug does not
inhibit any type of regulated cell death (Supplementary
Fig. 4a). Furthermore, we found that IL-22-dependent
activation of STAT3 in HT-29 cells and GM-CSF-
dependent STAT5 sensitivity in U937 cells were unaf-
fected by the presence of Phenhydan® (Supplementary
Fig. 4b), indicating that Phenhydan® does not generally
block cytokine-mediated signal transduction.
Since Phenhydan® suppresses TNFR1 signaling, we next
tested whether it inhibits other pathogen recognition- or
death receptor-initiated processes. To this end, we treated
cells with FasL, TRAIL, and TLR agonists, which can
induce apoptosis and necroptosis, depending on stimuli. As
shown in Fig. 4a–e, we found that Phenhydan® suppressed
FasL-, TRAIL-, and TLR3-agonist induced cell death,
which strongly suggests that Phenhydan® interferes with
death receptor signal transduction, most likely at an early
stage such as their integration into lipid rafts. TLR3 is not a
death receptor but is localized to and signals from acidiﬁed
compartments of the endolysosomal pathway, and it mainly
plays a role in the detection of nucleic acids of pathogens
[33]. Nevertheless, inhibition or elimination of caspase-8
during stimulation of TLR3 results in RIP3 kinase-
dependent programmed necrosis that occurs through TIR
domain-containing adapter-inducing interferon-β (TRIF)
[34]. TRIF, RIPK3, and MLKL promote cell death via a
pathway that is analogous to the RIPK1–RIPK3–MLKL
axis [7]. This mechanism may explain the protective effect
of Phenhydan® in TLR3-initiated cell death. Therefore, we
assessed whether Phenhydan®-mediated changes in the
plasma membrane also affected the ability of MLKL to
form pores, regardless the fact that the precise mechanism
of this permeabilization has not yet been clariﬁed so far
[35–37]. To this end, we made use of a constitutively active
form of MLKL (phosphomimetic S345D). Doxycycline-
inducible expression of this MLKL mutant was reported to
cause necroptosis independently of upstream signals [38].
Intriguingly, while induced expression of MLKLS345D
readily killed cells, in the presence of Phenhydan®
MLKLS345D was signiﬁcantly less potent in killing cells
(Fig. 4f). This suggests that Phenhydan®-mediated changes
of the lipid bilayer affect the ability of MLKL to form
membrane apertures. At the membrane, it may either
inﬂuence bilayer properties/structures or access target
membrane proteins such as voltage-gated sodium channels
to exert its pharmacologic action. The possibility that the
mere presence of Phenhydan® prevents or signiﬁcantly
reduces the doxycycline-induced expression of the con-
stitutively active MLKLS345D, which may lead to an incor-
rect attribution of protection from necroptosis, was ruled out
by direct comparison between MDFs isolated from MLKL-
ko animals, MDFs from MLKL-ko animals in which wild-
type MLKL was reconstituted, and the constitutively active
MLKL mutant S345D. At 7 h after the addition of dox-
ycycline, all inducible cells showed virtually identical pro-
tein expression of MLKL regardless of the presence or
absence of Phenhydan® (Supplementary Fig. 5).
The main purpose of our study was to identify an FDA-
approved drug that, independent of its clinical application,
possesses an inhibitory effect on pathophysiologic cell
death, which might be suitable for emergency use. Since
many inﬂammatory pathologies are driven by aberrant
TNF-induced cell death, we tested whether Phenhydan®
could be used in vivo to suppress death receptor-induced
cell death. To this end, we focused on clinically relevant
in vivo models associated with pathophysiologic death
receptor-induced cell death, such as renal IRI and immune-
mediated liver injury [39, 40]. Renal ischemia causes as
well as frequently exacerbates already existing acute kidney
disease (AKI) and chronic kidney disease [41]. For the
mouse mode of IRI, animals underwent 47 min of bilateral
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renal pedicle clamping followed by 48 h of reperfusion. As
described previously, such long-lasting ischemia is lethal in
untreated wild-type mice 72 h after reperfusion [39]. In this
setting, functional markers for the loss of kidney function
(elevated serum concentrations of creatinine and urea) were
signiﬁcantly reduced 48 h after reperfusion in the presence
of Phenhydan® (Fig. 5b, c). This indicates the effectiveness
and therapeutic potential of Phenhydan® for the treatment of
complex diseases driven by death receptor-induced cell
death. Our conclusion is supported by representative peri-
odic acid-Schiff-stained histomicrographs of the kidneys
(Fig. 5a) and corresponding quantiﬁcation of the injury
based on the renal damage scores (Fig. 5d). The well-
established TUNEL ﬂuorescence assay, which is used to
detect (Fig. 5f) and estimate the number of cells undergoing
regulated necrotic death (Fig. 5e), conﬁrmed at the cellular
level the protective effect of Phenhydan® in this clinically
relevant in vivo model.
To further corroborate the use of Phenhydan® as a potential
therapeutic agent for the treatment of diseases involving
pathophysiologic cell death by death receptors, we use a
murine model of inﬂammation-dependent hepatitis. Hepatitis
was induced by intravenous injection of the Lectin ConA,
which causes symptoms that resemble immune-mediated
hepatitis in humans [42]. In this model MLKL seems to act as
a central player because Mlkl-knockout animals are protected
from ConA injury and experimental hepatitis [40]. While
treatment with ConA resulted in liver damage and hepatitis,
co-treatment with Phenhydan® greatly diminished plasma
alanine aminotransferase (ALT) and aspartate aminotransfer-
ase (AST) concentrations, as well as considerably reduced
lactate dehydrogenase (LDH) activity (Fig. 6b–d). Moreover,
immunohistochemical analysis of these mice revealed sig-
niﬁcantly reduced liver tissue cell death following Phenhy-
dan® treatment (Fig. 6a). Just as in the IRI model, a TUNEL
ﬂuorescence assay was used to monitor (Fig. 6f) and evaluate
Fig. 4 The protective effect of Phenhydan® against regulated cell death
is not restricted to TNF-induced necroptosis. a HT-29 cells were sti-
mulated at 37 °C for 24 h with 200 ng/ml TRAIL+ 1 µM SMAC
mimetic SM164+ 25 µM zVAD in the absence or presence of 1 mM
Phenhydan®. b Similarly, primary MEFs were stimulated for 6 h at 37 °
C with 10 µg/ml TLR3 ligand+ 1 µM SMAC mimetic SM164+ 25
µM zVAD in the absence or presence of 1 mM Phenhydan®. Both
TRAIL and TLR3 ligand induced necroptotic cell death in a TNF-
independent manner. c–e Phenhydan® was also able to inhibit death
receptor-mediated apoptosis. c Primary BMDCs and d MEFs were
stimulated for 3 and 6 h, respectively, at 37 °C with 100 ng/ml TNFα
+ 1 µM SMAC mimetic SM164 in the absence or presence of 1 mM
Phenhydan®. e Furthermore, human Jurkat cells were stimulated for 4 h
at 37 °C with 100 ng/ml FasL. f Wild-type or mutated (S345D Mixed
lineage kinase domain-like protein) mouse dermal ﬁbroblasts (MDFs)
were induced at 37 °C with 0.5 µg/ml doxycycline for 7 h, before cells
were harvested and permeabilized in Frackelton buffer. As indicated,
1 mM Phenhydan® was added 30 min before induction. The cell death
that occurred in a–f was quantiﬁed by FACS analysis using the
indicated markers. Graphs show the mean ± SEM; n= 2–3 indepen-
dent experiments
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the number of cells undergoing regulated cell death (Fig. 6e)
in this clinically relevant in vivo model. The extent of cell
death induced by ConA, and especially the impressive pro-
tective effect of Phenhydan®, is illustrated in Fig. 6e, f.
Discussion
Receptor-interacting serine/threonine protein kinase 1
(RIPK1) has been shown to be a critical driver of various
pathways downstream of the death receptors TNFR1, FasL,
and TRAIL, as well as toll-like receptors. Hence, blocking
these pathways has the potential to result in a broad
therapeutic beneﬁt for multiple diseases such as ischemia-
reperfusion injury, myocardial infarction, sepsis, and mul-
tiple sclerosis. Since TNFα is involved in mediating a ple-
thora of human diseases, the inhibition of RIPK1 may
beneﬁt patients beyond the indications that are currently
being tested. Above all, GlaxoSmithKline (GSK) and
Denali Therapeutics have identiﬁed and optimized a set of
RIPK1 inhibitors and several human clinical trials as
treatments of inﬂammatory and neurodegenerative diseases
from ulcerative colitis and rheumatoid arthritis to amyo-
trophic lateral sclerosis (ALS) and Alzheimer’s disease
(AD) have been initiated [43]. Nevertheless, none of these
exciting compounds reached Phase-III clinical studies today
Fig. 5 Phenhydan® provides protection from ischemia-reperfusion
damage. The signiﬁcant therapeutic effect of Phenhydan® was evident
under exceptionally severe test conditions. For establishing a renal
ischemia-reperfusion injury model, all the mice (n= 8 per group)
underwent 47 min of bilateral renal pedicle clamping followed by 48 h
of reperfusion. In the verum group, Phenhydan® was added at a ﬁnal
concentration of 1 mM to the drinking water (renewed every day)
7 days before the onset of ischemia and until the end of the reperfusion
phase. a Periodic acid-Schiff-stained histomicrographs of the kidneys
exhibited diminished total organ damage in the Phenhydan®-treated
mice compared with the vehicle-treated animals (scale bar= 300 µm
[20×] and 200 µm [40×], respectively). Accordingly, we observed that
the vehicle-treated mice had signiﬁcantly lower plasma levels of serum
creatinine (b) and urea (c) than the Phenhydan®-treated animals. d The
protective effect of Phenhydan® in this model was conﬁrmed by
quantiﬁcation of the renal damage. e, f To illustrate the protective
effect of Phenhydan® at the cellular level, a TUNEL ﬂuorescence assay
was performed to detect (f) and quantify (e) cells undergoing regulated
necrotic death (in green) in this clinically relevant in vivo model.
DAPI was used for nuclear counterstaining (blue). Scale bar= 100 µM
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and accordingly, no pharmacologic inhibitor of RIPK1-
mediated cell death is currently in clinical use.
In the present study, we screened a selection of FDA-
approved drugs with structures related to the RIPK1 inhi-
bitor necrostatin-1 and identiﬁed the anti-epileptic drug
Phenhydan® in multiple cell types as a potent inhibitor of
both pro-inﬂammatory NF-κB signaling and aberrant cell
death. Furthermore, we were able to show that Phenhydan®
elicits these effects by inﬂuencing the membrane structure
and function of cells. The initial formation of TNF/TNFR
complexes is followed by secondary multimerization into
supramolecular clusters, and it is known that efﬁcient signal
initiation requires the formation of larger ligand/receptor
complexes [44]. It has been shown previously that besides
TNF/TNFR complex, a considerable fraction of Fas is
constitutively partitioned into cholesterol- and sphingolipid-
rich lipid rafts within the plasma membrane prior to ligation
at a level that is not changed after Fas engagement. How-
ever, Fas ligation might trigger compositional changes in
lipid rafts, suggesting that rafts represent the membrane site
from which, upon engagement by its ligand, Fas initiates its
signaling cascade [45]. Similarly, ligation of TRAILR1/2
localized to lipid rafts induces pro-cell death signaling,
whereas TRAIL receptors that are not associated with lipid
rafts mediate the activation of NF-κB [46]. Interestingly, it
was reported that drugs, which induced the localization of
Fig. 6 Phenhydan® has protective effects in an in vivo model of
inﬂammation-dependent hepatitis. The beneﬁcial effects of Phenhy-
dan® in diseases involving pathophysiologic necroptosis were con-
ﬁrmed in a murine model of inﬂammation-dependent hepatitis. Mice
(n= 10 per group) were subjected to ConA or saline treatment as
described in the Materials and Methods section and analyzed 7 h after
administration. a Immunohistochemical analysis revealed distinctly
reduced liver tissue necrosis and hepatocyte death in the Phenhydan®-
treated mice compared with the vehicle-treated animals (scale bar=
200 µm [20×] and 50 µm [40×], respectively). b–d Compared with the
control group, the Phenhydan®-treated animals had considerably
reduced plasma alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) concentrations as well as considerably reduced
lactate dehydrogenase (LDH) activity. e, f To visualize the protective
effect of Phenhydan®, we performed a TUNEL ﬂuorescence assay to
detect (f) and quantify (e) cells undergoing regulated necrotic death (in
green) in this model of liver injury. DAPI was used for nuclear
counterstaining (blue). Scale bar= 100 µM
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TRAILRs to lipid rafts, resulted in enhanced TRAIL-
mediated cell death [47]. According to our present data,
Phenhydan® has the opposite effect. This is consistent with
the protective effect of the drug in the course of regulated
cell death. Changes in lipid bilayer properties and lipid raft
formation at an early stage alter membrane function, pro-
viding an indirect way for this drug to interfere with death
receptor signal transduction, which goes beyond a simple
modulation of necrosome formation/activation and merely
inhibition of necroptotic cell death. The heterogeneity of the
lipid composition of different cell lines is well known.
Further, the number of physically distinct lipid raft domains
in living cells is likely to be enormous [48]. Therefore, the
clear separation of detergent-insoluble fractions from solu-
ble ones is not often possible, and the degree of separation
differs across cell lines. Since amphiphilic pharmacological
compounds such as Phenhydan® can be adsorbed at the
bilayer interface and alter lipid bilayer properties [49], it is
likely that Phenhydan® acts as a modulator of death receptor
signaling by affecting the lipid bilayer properties of the
plasma membrane, thus modifying the behavior of a range
of membrane-bound proteins, including TNFR1.
Thus, changes in lipid bilayer properties, such as their
ability to form lipid rafts or allow MLKL pore formation,
could ultimately alter death receptor-mediated apoptosis
and necroptosis. Phenhydan®, therefore, might inﬂuence
death receptor signaling in lipid rafts, and conditional
redistribution of TNFR1 in the plasma membrane is only
one of the many possible mechanisms by which this drug
regulates the efﬁciency of TNF signaling. At the molecular
level, our statement is supported by the experiment shown
in Fig. 3f. Determination of ASMase activity in the pre-
sence or absence of Phenhydan® was performed only in the
presence of TNF but without the addition of the pan-caspase
inhibitor zVAD. Upon binding of TNF to its corresponding
receptor, internalization of this complex occurs immedi-
ately, and it was shown previously that this event causes
rapid endosome formation [50]. The receptor-containing
endosomes fuse with lysosomes, resulting in the formation
of multivesicular bodies and bringing lysosomal ASMase
into close contact with caspases, which cleave the 72 kDa
pro-form of ASMase into a 57 kDa ASMase fragment and
thereby activate the enzyme. Our data indicate that ASMase
activation after TNF/TNFR1 internalization is signiﬁcantly
inhibited in the presence of Phenhydan®.
Moreover, by using two mouse models of death receptor-
driven pathology our data clearly demonstrate that Phen-
hydan® treatment suppresses death receptor-induced cell
death also in vivo. On the one hand, we found that the
anticonvulsive drug Phenhydan® attenuated functional
markers of acute kidney injury (AKI) and histological
damage, indicating the effectiveness and therapeutic
potential of Phenhydan® for the treatment of complex
processes driven by death receptor-induced cell death like
ischemia-reperfusion injury (IRI). In this context should be
mentioned that AKI is associated with a high morbidity rate
and is potentially lethal, and is therefore an emergency
medical problem. Our limited understanding of the complex
cell death mechanism in the process of AKI impedes the
development of desirable therapeutics. To date, there is no
effective therapy for AKI in clinical routine. Furthermore,
we found that Phenhydan® ameliorates inﬂammation-
induced programmed hepatocyte cell death, suggesting
that clinical application of the drug in patients with steatosis
and primary biliary cirrhosis is feasible with an inhibitor
that is already available.
Given our ﬁndings, we suggest to repurpose Phenhydan®
in settings where aberrant death receptor-mediated cell
death might contribute to human inﬂammation driven
pathologies, such as myocardial infarction, stroke, and
organ/graft IRI. The well-deﬁned safety proﬁle of Phenhy-
dan® which is currently used in the clinic as anticonvulsant
recommends it for Phase-III clinical trials in which the
utility of the drug for the treatment of the aforementioned
cell death-associated diseases should be veriﬁed. The
application for a multicenter, randomized study using
Phenhydan®, in which the objective is to reduce infarct
volume during stent-retriever thrombectomy in acute
ischemic stroke by inhibiting regulated cell death, has
recently been submitted.
Materials and methods
Cell lines
L929, NIH3T3, HT-29, U937, and Jurkat cells were
obtained from the American Type Culture Collection
(Manassas, VA, USA). The isolation and immortalization
of mouse dermal ﬁbroblasts (MDFs) from the dermis of
Mlkl-knockout and congenic wild-type mice have been
described previously [51]. The MDF cell lines, L929,
NIH3T3, and HT-29 were cultured in DMEM (Gibco®;
Thermo Fisher Scientiﬁc) supplemented with 10% (vol/
vol) FCS (PAN-Biotech GmbH, Aidenbach, Germany),
100 U/ml penicillin, and 100 μg/ml streptomycin (Merck
Millipore GmbH, Darmstadt, Germany). Jurkat cells were
cultured in RPMI 1640 medium (Gibco®; Thermo Fisher
Scientiﬁc) supplemented with 5% (vol/vol) FCS, 100 U/
ml penicillin, and 100 μg/ml streptomycin. U937 cells
were cultured in RPMI 1640 medium supplemented with
10% (vol/vol) FCS, 100U/ml penicillin, 100 μg/ml strep-
tomycin, 1 mM sodium pyruvate, and 0.25% D-(+ )-glu-
cose (Sigma-Aldrich Chemie GmbH, Taufkirchen,
Germany). All cell lines were cultured in a humidiﬁed 5%
CO2 atmosphere.
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Primary cells
Primary MEFs were generated from E13.5 embryos. After
removing the placenta, yolk sac, head, and dark red organs,
the embryos were ﬁnely minced and digested for 20 min in
0.25% trypsin. A single-cell suspension was then obtained
by pipetting the digested embryos up and down. To gen-
erate bone marrow-derived macrophages, bone marrow
cells from the tibias and femurs of 2-month-old mice were
seeded in non-coated Petri dishes and cultured for 6 days in
DMEM supplemented with 10% (vol/vol) FCS and 20%
(vol/vol) L929 mouse ﬁbroblast-conditioned medium. Pri-
mary cells were cultured in a humidiﬁed 5% CO2
atmosphere.
Reagents and antibodies
Recombinant puriﬁed TNFα, the Annexin V-FITC anti-
body, and the 7-amino-actinomycin D antibody were pur-
chased from BioLegend (London, UK). Recombinant
untagged TRAIL, TLR3 ligand, FLAG-tagged TNFα, GM-
CSF, IL-22, anti-cIAP1, and anti-Heat shock protein 90
were obtained from Enzo Life Sciences GmbH (Lörrach,
Germany). Fc-tagged human TNFα was manufactured by
SinoBiological, the bivalent SMAC mimetic SM164 by
AdooQ Biosciences, and RSL3 by Selleckchem (all pur-
chased from Hölzel Diagnostika Handels GmbH, Cologne,
Germany). Biotinylated TNFα was purchased from Invi-
trogen (Carlsbad, CA, USA). Alexa Fluor™ 488-
conjugated Streptavidin, CellMask™, and cholera toxin
subunit B (CTxB) Alexa Fluor™ 594 conjugate were pur-
chased from Thermo Fisher Scientiﬁc (Darmstadt, Ger-
many). The pan-caspase inhibitor zVAD-fmk was
purchased from Bachem (Weil am Rhein, Germany). ConA
was obtained from Merck Millipore. α-human Fas (clone
7C11) was purchased from Immunotech (Marseille,
France). PR619, the monoclonal α-FLAG M2 antibody,
sucrose, MβCD, imidazole, hydantoin, and propidium
iodide (PI) solution were purchased from Sigma-Aldrich
Chemie GmbH. Drugs tested in this work were obtained
from followed companies: Tavor® (Pﬁzer Pharma GmbH,
Berlin, Germany), Dormicum® (Roche Pharma AG, Rein-
ach, Switzerland), Brevimytal® (Hikma Pharma GmbH,
Martinsried, Germany), Luminal® and Phenhydan® (both
from Desitin Arzneimittel GmbH, Hamburg, Germany).
The anti-ubiquitin antibody was obtained from Dako (Bio-
zol Diagnostica Vertrieb GmbH, Eching, Germany) and the
α-SHARPIN antibody was purchased from Proteintech
(Manchester, UK). Erastin, GSK’872 and the anti-MLKL
antibody (clone 3H1) were obtained from Calbiochem®
(Merck Millipore). The murine MLKL inhibitor
GW806742X was purchased from Biomol (Hamburg,
Germany). Ferrostatin-1 was purchased from Xcess
Biosciences Inc. (San Diego, CA, USA). The anti-human as
well as the anti-mouse monoclonal phospho-MLKL anti-
bodies, the anti-cholera toxin subunit B (CTxB) antibody,
and the anti-TNFR1 antibody were obtained from Abcam
(Berlin, Germany). The anti-RIPK3 antibody (human- and
mouse-speciﬁc) was obtained from ProSci Incorporated
(Hölzel Diagnostika Handels GmbH). Anti-RIPK1 (human-
and mouse-speciﬁc), anti-human and anti-murine phospho-
RIPK1, anti-murine phospho-RIPK3, anti-JNK, anti-phos-
pho-JNK, anti-IκBα, anti-phospho-IκBα, anti-MK2, anti-
phospho-MK2, anti-p38, anti-phospho-p38, anti-p65, anti-
phospho-p65, anti-phospho-STAT3/5, anti-Flotillin-2, and
the β-actin antibody were purchased from Cell Signaling
Technology Europe BV (Frankfurt, Germany).
Assessment of cell death in vitro
Phosphatidylserine exposure to the outer cell membrane of
apoptotic cells or inner plasma membrane of necrotic cells
and incorporation of 7-amino-actinomycin D into necrotic
cells was quantiﬁed by FACS analysis. Stainings were
performed according to the manufacturer’s instructions
(BioLegend). Fluorescence was analyzed using an FC-500
ﬂow cytometer (Beckman Coulter GmbH, Krefeld,
Germany).
Analysis of cell death by western blotting
For immunoblotting, cells were lysed in ice-cold 10 mM
Tris-HCl (pH 7.5), 50 mM NaCl, 1% Triton X-100, 30 mM
Na4P2O7, 50 mM NaF, 100 μM Na3VO4, 2 μM ZnCl2, and
1 mM C7H7FO2S (PMSF) (modiﬁed Frackelton buffer).
Insoluble material was removed by centrifugation
(14,000 × g, 10 min, 4 °C) and protein concentration was
determined using a commercial Bradford assay kit accord-
ing to the manufacturer’s instructions (Bio-Rad Labora-
tories GmbH, Munich, Germany). Equal amounts of protein
(20 μg per lane) were resolved by reducing SDS/PAGE and
transferred to a polyvinylidene ﬂuoride (PVDF) membrane
(GE Healthcare Life Sciences, Freiburg, Germany). Wes-
tern blots were performed using the speciﬁc primary anti-
bodies mentioned above and corresponding secondary
horseradish peroxidase-linked polyclonal antibodies
obtained from Abcam (Berlin, Germany). Immune com-
plexes were visualized by enhanced chemiluminescence
(ECL).
Mice
Mice used in this study were of the C57BL/6 background
and were purchased from Janvier Labs (Saint Berthevin
Cedex, France). All mice were carefully matched for age,
sex, and weight. For our analyses, the animals used were
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male mice at an age of 8 weeks. All mice were kept on a
standard diet and a 12-h day-night rhythm. All in vivo
experiments were performed according to the Protection of
Animals Act with the approval of German and French local
authorities.
Ischemia-reperfusion injury
Induction of murine kidney IRI was performed via a
midline abdominal incision and bilateral renal pedicle
clamping for 47 min using microaneurysm clamps (Aes-
culap, Inc., Center Valley, PA USA). Throughout the
surgical procedure, the body temperature of the mice was
maintained at between 36 °C and 37 °C by continuous
monitoring using a temperature-controlled self-regulated
heating system (Fine Science Tools GmbH, Heidelberg,
Germany). After removal of the clamps, reperfusion of the
kidneys was conﬁrmed visually. The abdomen was closed
in two layers using standard 6-0 sutures. To maintain ﬂuid
balance, all of the mice were supplemented with 1 ml of
prewarmed PBS administered intraperitoneally directly
after surgery. The mice were sacriﬁced 48 h after reper-
fusion. Serum creatinine and urea values were measured
in the Central laboratory of the University Hospital
Schleswig-Holstein, Kiel (Germany). IRI experiments
were performed in a double-blinded manner. Where
indicated, Phenhydan® was added at a ﬁnal concentration
of 1 mM to the drinking water (renewed every day) of the
mice 7 days before the onset of ischemia and until the end
of the reperfusion phase.
In vivo model of liver injury
C57BL/6 mice were subjected to ConA or saline treatment
and sacriﬁced 7 h later. ConA was administered intrave-
nously at a concentration of 15 mg/kg body weight. Where
indicated, a singular injection of Phenhydan® was admi-
nistered intraperitoneally at a concentration of 34 mg/kg
body weight (total volume per mouse was 200 µl) 30 min
before ConA administration. Appropriate amount of PBS
(200 µl per mouse) was applied as vehicle control. The
plasma concentrations of alanine aminotransferase, aspar-
tate aminotransferase, and lactate dehydrogenase were
measured in the Central laboratory of the Université Pierre
et Marie Curie, Paris (France) as well as in the Central
laboratory of the University Hospital Schleswig-Holstein,
Kiel (Germany).
Histologic, immunohistochemical, and morphologic
assessments
Kidney and liver biopsies were ﬁxed in 4% neutral-buffered
formaldehyde and embedded in parafﬁn. The 3-μm sections
produced were dewaxed, rehydrated, and subjected to per-
iodic acid-Schiff staining (kidney) and haematoxylin and
eosin (liver) according to routine protocols. Stains were
evaluated blinded by an experienced pathologist. Sections
were evaluated using an U-DO3 microscope (Olympus
Corp., Tokyo, Japan). Representative photomicrographs
were taken using a Zeiss system (an Axioplan microscope
with an MRT digital camera and Axiovision Software; Carl
Zeiss AG, Oberkochen, Germany).
To analyze cell death of the tissue sections, the TdT-
mediated dUTP nick end labeling (TUNEL) assay was
performed using the ﬂuorescence detection kit according
to the manufacturer’s instructions (Promega, Mannheim,
Germany). Brieﬂy, tissue sections were dewaxed, rehy-
drated, ﬁxed in 4% paraformaldehyde and permeabilized
with Proteinase K for 10 min at RT. Following this, the
sections were equilibrated with the provided buffer for 10
min and labeled with the TdT reaction mix for 60 min at
37 °C in a humidiﬁed dark environment. To stop the
labeling reactions, sections were incubated with the pro-
vided stopping buffer for 15 min at RT in the dark. The
sections were then washed with PBS for 5 min. Finally,
the sections were mounted with ﬂuorescence-mounting
media (Dako, Glostrup, Denmark) containing 4′,6-Dia-
midin-2-phenylindol (DAPI) for cell nuclei counter-
staining. Fluorescence micrographs were taken using
Zeiss Axio Imager Z1 ﬂuorescence microscope (Carl
Zeiss AG, Oberkochen, Germany) at magniﬁcations of
20× and 40× magniﬁcation using a standard ﬂuorescein
ﬁlter set to view the green ﬂuorescence at 520 nm, and
blue ﬂuorescence of DAPI at 380 nm. Quantiﬁcation of
TUNEL-positive cells was performed manually by two
blinded observers and reproduced in triplicate by each of
them.
Complex-I puriﬁcation
MEFs were seeded in 15-cm dishes and treated as indicated
with 3x FLAG-TNFα (5 mg/ml). The medium was removed
and the plates were washed with ice-cold PBS. Then, the
plates were frozen at−80 °C. The plates were later thawed
on ice and the cells were lysed in 1% Triton X-100 lysis
buffer (30 mM Tris-HCl [pH 7.4], 120 mM NaCl, 2 mM
EDTA, 2 mM KCl, 10% glycerol, and 1% Triton X-100)
plus protease inhibitors and 10 mM PR619 (inhibitor of
ubiquitin isopeptidases). The cell lysates were rotated at 4 °
C for 20 min and then clariﬁed at 4 °C for 30 min at
14,000 × g. The proteins were immunoprecipitated using 20
ml of α-FLAG M2 beads with rotation overnight at 4 °C.
For the 0 min sample, 5 mg/ml of FLAG-TNFα was added
post-lysis. The beads were washed four times in lysis buffer
and the samples were eluted by boiling in 60 µl of 1x SDS
loading dye.
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Immunoprecipitation assay
For TNFR1 immunoprecipitation (IP), 1 × 107 U937 cells
were preincubated for 30 min with 1mM Phenhydan® or the
appropriate amount of DMSO as a vehicle control. Next, the
cells were treated for 0, 5, 15, 30, and 60min, respectively, at
37 °C with 100 ng/ml FLAG-tagged or Fc-tagged human
TNFα. The cells were collected into tubes pre-cooled on ice
containing ice-cold PBS, centrifuged at 1,500 RPM, washed
with ice-cold PBS, lysed in IP buffer (50mM Tris-HCl [pH
7.4], 150mM NaCl, 1% NP-40, 0.25%, Na-deoxycholate, 1%
Triton X-100, 1 mM EDTA, 100 µM Na3VO4, and 1mM
C7H7FO2S (PMSF) and kept on ice for 20 min. For the 0min
sample, 100 ng/ml TNFα was added post-lysis. The cell
lysates were clariﬁed at 4 °C for 10min at 14,000 × g. For IP,
the lysates were incubated with 50 µl of µMACS™ Protein G
MicroBeads (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany) and rotated at 4 °C for 2 h. The lysates were
applied to µ Columns (Miltenyi Biotec GmbH) pre-wetted
with IP buffer, washed with IP buffer, and eluted with 40 µl of
pre-warmed 95 °C SDS loading buffer. Of each sample
(eluate), 20 µl was loaded for western blotting analysis.
Acid Sphingomyelinase activity
Acid Sphingomyelinase (ASMase) activity was determined
using an Acidic Sphingomyelinase Assay Kit from Abcam
(Berlin, Germany) following the manufactures instructions.
As indicated, U937 were pretreated at 37 °C for 30 min with
vehicle or 1 mM Phenhydan® followed by a stimulation with
100 ng/ml human TNFα for 30 min at 37 °C. Then, cells
were lysed in ice-cold 10 mM Tris-HCl (pH 7.5), 50 mM
NaCl, 1% Triton X-100, 30 mM Na4P2O7, 50 mM NaF,
100 μM Na3VO4, 2 μM ZnCl2, and 1 mM C7H7FO2S
(PMSF) (modiﬁed Frackelton buffer). Cellular debris was
removed by centrifugation (14,000 × g, 10 min, 4 °C).
Lysate of 1 × 106 cells each were used to determine ASMase
activity by measuring of the ﬂuorescence (λex 540 nm and
λem 590 nm) in the Inﬁnite® 200 PRO plate reader from
Tecan (Männedorf, Switzerland).
Sucrose gradient
We incubated 1 × 108 U937 cells in 3 ml of RPMI 1640
medium at 37 °C for 30 min with 1 mM Phenhydan®, 10
mM MβCD, or vehicle alone (control). Subsequently, the
cells were collected by centrifugation at 1,500 RPM,
washed with ice-cold PBS, and incubated with 2 ml TX-
buffer (25 mM Tris [pH 6.5], 150 mM NaCl, 5 mM EDTA,
1% Triton X-100 including protease inhibitor cocktail) at 4
°C for 3 h followed by sonication for 15 sec. The cell lysate
was mixed with an equal volume of 95% sucrose (w/v) in T-
buffer (25 mM Tris [pH 6.5], 150 mM NaCl, 5 mM EDTA)
and placed into ultracentrifugation tubes. The cell lysate
mixtures were overlaid sequentially with 4 ml of 35% (w/v)
sucrose and 4 ml of 5% (w/v) sucrose, each in T-buffer, and
centrifuged using an SW 32 Ti rotor (Beckman Coulter
GmbH) for 19 h at 143,000 × g. We collected 1 ml of the
fractions (numbered according to Fig. 3g from 1 to 7) from
the top of the gradient and used them for protein analysis
via western blotting.
ImageStream analysis
For quantiﬁcation of TNFR1 internalization by imaging
ﬂow cytometry, cells were incubated for 15 min at room
temperature with vehicle or 1 mM Phenhydan®, respec-
tively, followed by sedimentation and cooling on ice for 15
min. Labeling of TNFR1 with 100 ng/ml biotinylated TNFα
and 5 µg/ml Alexa Fluor™ 488-conjugated Streptavidin
was performed on ice for 20 min. To facilitate receptor
internalization, the temperature was raised to 37 °C with
pre-warmed medium for 30 min. Thereafter, the cells were
ﬁxed in 2% paraformaldehyde/PBS for 20 min without
permeabilization. CellMask™ Deep Red plasma membrane
stain (1:10,000 dilution of the stain) was added for the ﬁnal
5 min. The cells were washed twice with PBS and the cell
pellet was resuspended in 20 µl of PBS.
The ImageStream Mark II was used for cell analysis. At
least 5000 images were acquired, detecting the internaliza-
tion probes biotinylated TNFα/Alexa Fluor™ 488-
conjugated Streptavidin (excitation: 488 nm) on Channel 2
and the cell surface label CellMask™ (excitation: 642 nm)
on Channel 5. We applied the internalization wizard of the
software Amnis IDEAS (version 6.0.154.0) according to the
instruction manual, to determine the TNF/TNFR1 inter-
nalization rate in vehicle-treated versus Phenhydan®-treated
U937 cells. For monitoring time-dependent CellMask™
ﬂuorescence in the presence of Phenhydan® 3 × 104 U937
per value were resuspended in 300 µl PBS and pretreated
with 1 mM Phenhydan® or 10 mM methyl-β-cyclodextrin
(MβCD) for 30 min, representing the time frame from −30
to 0 min. Following this, CellMask™ (1:10,000 dilution of
the stain) was added in each well (0 up to 30 min). Con-
versely, cells were ﬁrst incubated for 30 min with Cell-
Mask™ (−30 to 0 min) and then mixed with 1 mM
Phenhydan® (0 to 30 min). The measurements were per-
formed at 37 °C in a black 96-well plate, and ﬂuorescence
(λex 642 nm and λem 666 nm) was measured with the Inﬁ-
nite® 200 PRO plate reader from Tecan. Samples were
measured in triplicate every 15 min over a period of 1 h.
The ﬂuorescence intensity of cholera toxin subunit B
(CTxB) conjugated with Alexa Fluor™ 594 was also
measured via ﬂow cytometry using ImageStream Mark II
(excitation: 590 nm on Channel 5). As indicated, U937 cells
were pretreated at 37 °C for 30 min with vehicle or 1 mM
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Phenhydan®. Afterwards, the cells were washed with ice-
cold PBS and stained with 1 µg/ml CTxB conjugated with
Alexa Fluor™ 594 in PBS for 10 min at 4 °C in the dark.
Then, the cells were washed three times with PBS, and an
α-CTxB antibody (1:200) was added for 15 min at 4 °C in
the dark to crosslink the CTxB in the lipid rafts. Subse-
quently, the cells were washed three times with ice-cold
PBS and ﬁxated with 4% paraformaldehyde for 10 min at
room temperature in the dark, washed again and resus-
pended in PBS for the ﬂow cytometer analysis.
Statistical methods and analyses
For all experiments, the differences between datasets were
considered statistically signiﬁcant when p-values were
<0.05, if not otherwise speciﬁed. Statistical comparisons
were performed using the two-tailed Student’s t test.
Asterisks are used in the ﬁgures to specify statistical sig-
niﬁcance (*p < 0.05; **p < 0.02; ***p < 0.001). The results
are presented as means ± SD unless otherwise speciﬁed.
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